| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,1
* Neuroscience Research Group, University of Quebec at Trois-Rivieres, Trois-Rivieres, Quebec, Canada; and
Department of Cell Biology, Center for Models of Human Disease, IGSP, Duke University, Durham, North Carolina, USA
1Correspondence: M.G.C.: Department of Cell Biology, Center for Models of Human Disease, IGSP, Box 3287, Duke University, Durham, NC, 27710, USA; E-mail: caron002{at}mc.duke.edu or M.C.: Neuroscience Research Group, University of Quebec at Trois-Rivieres, C.P. 500, Trois-Rivieres, Quebec G9A 5H7, Canada. E-mail: cyrmi{at}uqtr.ca
ABSTRACT
An expansion in the CAG repeat of the IT15 (huntingtin) gene underlies the development of Huntington’s disease (HD), but the basis for the specific vulnerability of dopamine-receptive striatal neurons remains unclear. To examine the potential role of the dopamine system in the emergence of pathological conditions in HD, we generated a double mutant mouse strain with both enhanced dopamine transmission and endogenous expression of a mutant huntingtin gene. This strain was generated by crossing the dopamine transporter knock-out mouse, which exhibits a 5-fold elevation in extracellular dopamine levels in the striatum and locomotor hyperactivity, to a knock-in mouse model of HD containing 92 CAG repeats. These double mutant mice exhibited an increased stereotypic activity at 6 months of age, followed by a progressive decline of their locomotor hyperactivity. Expression of the mutated huntingtin did not alter dopamine or its metabolite levels in normal or dopamine transporter knock-out mice. However, the mutant huntingtin protein aggregated much earlier and to a greater extent in the striatum and other dopaminergic brain regions in the hyperdopaminergic mouse model of HD. Furthermore, the formation of neuropil aggregates in the striatum and other regions of hyperdopaminergic HD mice was observed at 4 months of age, well before similar events occurred in normal HD mice (12 months). These findings indicate that dopamine contributes to the deleterious effects of mutated huntingtin on striatal function, and this is accompanied by enhanced formation of huntingtin aggregates.—Cyr, M., Sotnikova, T. D., Gainetdinov, R. R., Caron, M. G. Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin.
This article has been cited by other articles:
|
|
 |
|
  P. Paoletti, I. Vila, M. Rife, J. M. Lizcano, J. Alberch, and S. Gines Dopaminergic and Glutamatergic Signaling Crosstalk in Huntington's Disease Neurodegeneration: The Role of p25/Cyclin-Dependent Kinase 5 J. Neurosci., October 1, 2008; 28(40): 10090 - 10101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Waugh, V. S. Miller, R. S. Chudnow, and M. M. Dowling Juvenile Huntington Disease Exacerbated by Methylphenidate: Case Report J Child Neurol, July 1, 2008; 23(7): 807 - 809. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Benchoua, Y. Trioulier, E. Diguet, C. Malgorn, M.-C. Gaillard, N. Dufour, J.-M. Elalouf, S. Krajewski, P. Hantraye, N. Deglon, et al. Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II Hum. Mol. Genet., May 15, 2008; 17(10): 1446 - 1456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Chen, Y. Ding, B. Cagniard, A. D. Van Laar, A. Mortimer, W. Chi, T. G. Hastings, U. J. Kang, and X. Zhuang Unregulated Cytosolic Dopamine Causes Neurodegeneration Associated with Oxidative Stress in Mice J. Neurosci., January 9, 2008; 28(2): 425 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-S. Tang, X. Chen, J. Liu, and I. Bezprozvanny Dopaminergic Signaling and Striatal Neurodegeneration in Huntington's Disease J. Neurosci., July 25, 2007; 27(30): 7899 - 7910. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
